Exendin-4 and liraglutide increased mucin production in airways via p38 signaling, worsening emphysematous features — cautioning against inhaled GLP-1 drugs in patients with obstructive lung diseases.
Mucus increase + worse emphysemaGLP-1 agonists upregulated mucin via p38 and exacerbated obstructive lung disease phenotypes in mice
What the researchers found
GLP-1 receptor agonists upregulate mucin expression in airways via p38 MAPK, exacerbating emphysematous phenotypes in obstructive lung disease models.
Why it matters
Millions of people use GLP-1 drugs for diabetes and obesity. If these drugs worsen lung disease, patients with concurrent COPD or asthma need careful monitoring — especially as inhaled GLP-1 delivery is explored.
The numbers in context
Exendin-4 and liraglutide upregulated mucin; p38 MAPK activation; worsened emphysema in obstructive model; GLP-1R highly expressed in lung
How the study worked
Combined in-vitro (airway epithelial cells) and in-vivo (mouse) studies testing exendin-4 and liraglutide effects on mucin expression and pulmonary pathology under normal and obstructive conditions.
Who was studied
Normal airway cells, normal mice, and obstructive lung disease mouse models treated with exendin-4 or liraglutide
What this study cannot tell us
Mouse and cell culture models — human relevance not confirmed; intratracheal delivery may produce higher local concentrations than systemic administration; short-term study.
How to read the evidence
Consistent findings across in-vitro and in-vivo models with mechanistic pathway identification, but limited to animal models without clinical confirmation.
When this study was published
Published in 2020; with GLP-1 agonist use expanding dramatically, pulmonary effects warrant clinical investigation.
The bigger picture
This study reveals an unexpected adverse effect of GLP-1 signaling in the lungs, adding nuance to the otherwise positive therapeutic profile of GLP-1 receptor agonists.
Questions still open
- Do systemic GLP-1 agonists (subcutaneous injection) also increase lung mucus production in patients?
- Are COPD patients on GLP-1 drugs at higher risk for exacerbations?
- Could p38 inhibitors mitigate the pulmonary side effects of GLP-1 therapy?
Common questions
Can GLP-1 drugs affect the lungs?
Should people with lung disease avoid GLP-1 drugs?
Read the original research
Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
Biochemical and biophysical research communications, 524(2), 332-339
Citation
Nohara, Hirofumi; Nakashima, Ryunosuke; Kamei, Shunsuke; Fujikawa, Haruka; Ueno-Shuto, Keiko; Kawakami, Taisei; Eto, Yuka; Suico, Mary Ann; Li, Jian-Dong; Kai, Hirofumi; Shuto, Tsuyoshi. (2020). Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.. Biochemical and biophysical research communications, 524(2), 332-339. https://doi.org/10.1016/j.bbrc.2020.01.081